دورية أكاديمية
Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
| العنوان: | Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer |
|---|---|
| المساهمون: | Juliann Chmielecki, Jhanelle E Gray, Ying Cheng, Yuichiro Ohe, Fumio Imamura, Byoung Chul Cho, Meng-Chih Lin, Margarita Majem, Riyaz Shah, Yuri Rukazenkov, Alexander Todd, Aleksandra Markovets, J Carl Barrett, Ryan J Hartmaier, Suresh S Ramalingam, Cho, Byoung Chul |
| بيانات النشر: | Nature Pub. Group |
| سنة النشر: | 2023 |
| مصطلحات موضوعية: | Carcinoma, Non-Small-Cell Lung* / drug therapy, Non-Small-Cell Lung* / genetics, ErbB Receptors / genetics, Humans, Lung Neoplasms* / drug therapy, Lung Neoplasms* / genetics, Mutation, Protein Kinase Inhibitors / pharmacology, Protein Kinase Inhibitors / therapeutic use |
| الوصف: | Osimertinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), potently and selectively inhibits EGFR-TKI-sensitizing and EGFR T790M resistance mutations. In the Phase III FLAURA study (NCT02296125), first-line osimertinib improved outcomes vs comparator EGFR-TKIs in EGFRm advanced non-small cell lung cancer. This analysis identifies acquired resistance mechanisms to first-line osimertinib. Next-generation sequencing assesses circulating-tumor DNA from paired plasma samples (baseline and disease progression/treatment discontinuation) in patients with baseline EGFRm. No EGFR T790M-mediated acquired resistance are observed; most frequent resistance mechanisms are MET amplification (n = 17; 16%) and EGFR C797S mutations (n = 7; 6%). Future research investigating non-genetic acquired resistance mechanisms is warranted. © 2023. The Author(s). ; open |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 2041-1723 |
| العلاقة: | NATURE COMMUNICATIONS; J02293; OAK-2023-01384; https://ir.ymlib.yonsei.ac.kr/handle/22282913/195303Test; T202302907; NATURE COMMUNICATIONS, Vol.14(1) : 1070, 2023-02 |
| DOI: | 10.1038/s41467-023-35961-y |
| الإتاحة: | https://doi.org/10.1038/s41467-023-35961-yTest https://ir.ymlib.yonsei.ac.kr/handle/22282913/195303Test |
| حقوق: | CC BY-NC-ND 2.0 KR |
| رقم الانضمام: | edsbas.59145088 |
| قاعدة البيانات: | BASE |
Full Text Finder | ResultId |
1 |
|---|---|
| Header |
edsbas BASE edsbas.59145088 975 3 Academic Journal academicJournal 975.149597167969 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsbas&AN=edsbas.59145088&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://doi.org/10.1038/s41467-023-35961-y# [Name] => EDS - BASE [Category] => fullText [Text] => View record in BASE [MouseOverText] => View record in BASE ) [1] => Array ( [Url] => https://resolver.ebscohost.com/openurl?custid=s6537998&groupid=main&authtype=ip,guest&sid=EBSCO:edsbas&genre=article&issn=20411723&ISBN=&volume=&issue=&date=20230101&spage=&pages=&title=Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer&atitle=Candidate%20mechanisms%20of%20acquired%20resistance%20to%20first-line%20osimertinib%20in%20EGFR-mutated%20advanced%20non-small%20cell%20lung%20cancer&id=DOI:10.1038/s41467-023-35961-y [Name] => Full Text Finder (s6537998api) [Category] => fullText [Text] => Full Text Finder [Icon] => https://imageserver.ebscohost.com/branding/images/FTF.gif [MouseOverText] => Full Text Finder ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
)
Array ( [Name] => Author [Label] => Contributors [Group] => Au [Data] => Juliann Chmielecki<br />Jhanelle E Gray<br />Ying Cheng<br />Yuichiro Ohe<br />Fumio Imamura<br />Byoung Chul Cho<br />Meng-Chih Lin<br />Margarita Majem<br />Riyaz Shah<br />Yuri Rukazenkov<br />Alexander Todd<br />Aleksandra Markovets<br />J Carl Barrett<br />Ryan J Hartmaier<br />Suresh S Ramalingam<br />Cho, Byoung Chul ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => Nature Pub. Group ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2023 ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22Carcinoma%22">Carcinoma</searchLink><br /><searchLink fieldCode="DE" term="%22Non-Small-Cell+Lung*+%2F+drug+therapy%22">Non-Small-Cell Lung* / drug therapy</searchLink><br /><searchLink fieldCode="DE" term="%22Non-Small-Cell+Lung*+%2F+genetics%22">Non-Small-Cell Lung* / genetics</searchLink><br /><searchLink fieldCode="DE" term="%22ErbB+Receptors+%2F+genetics%22">ErbB Receptors / genetics</searchLink><br /><searchLink fieldCode="DE" term="%22Humans%22">Humans</searchLink><br /><searchLink fieldCode="DE" term="%22Lung+Neoplasms*+%2F+drug+therapy%22">Lung Neoplasms* / drug therapy</searchLink><br /><searchLink fieldCode="DE" term="%22Lung+Neoplasms*+%2F+genetics%22">Lung Neoplasms* / genetics</searchLink><br /><searchLink fieldCode="DE" term="%22Mutation%22">Mutation</searchLink><br /><searchLink fieldCode="DE" term="%22Protein+Kinase+Inhibitors+%2F+pharmacology%22">Protein Kinase Inhibitors / pharmacology</searchLink><br /><searchLink fieldCode="DE" term="%22Protein+Kinase+Inhibitors+%2F+therapeutic+use%22">Protein Kinase Inhibitors / therapeutic use</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Osimertinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), potently and selectively inhibits EGFR-TKI-sensitizing and EGFR T790M resistance mutations. In the Phase III FLAURA study (NCT02296125), first-line osimertinib improved outcomes vs comparator EGFR-TKIs in EGFRm advanced non-small cell lung cancer. This analysis identifies acquired resistance mechanisms to first-line osimertinib. Next-generation sequencing assesses circulating-tumor DNA from paired plasma samples (baseline and disease progression/treatment discontinuation) in patients with baseline EGFRm. No EGFR T790M-mediated acquired resistance are observed; most frequent resistance mechanisms are MET amplification (n = 17; 16%) and EGFR C797S mutations (n = 7; 6%). Future research investigating non-genetic acquired resistance mechanisms is warranted. © 2023. The Author(s). ; open ) Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => article in journal/newspaper ) Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English ) Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 2041-1723 ) Array ( [Name] => NoteTitleSource [Label] => Relation [Group] => SrcInfo [Data] => NATURE COMMUNICATIONS; J02293; OAK-2023-01384; https://ir.ymlib.yonsei.ac.kr/handle/22282913/195303; T202302907; NATURE COMMUNICATIONS, Vol.14(1) : 1070, 2023-02 ) Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.1038/s41467-023-35961-y ) Array ( [Name] => URL [Label] => Availability [Group] => URL [Data] => https://doi.org/10.1038/s41467-023-35961-y<br />https://ir.ymlib.yonsei.ac.kr/handle/22282913/195303 ) Array ( [Name] => Copyright [Label] => Rights [Group] => Cpyrght [Data] => CC BY-NC-ND 2.0 KR ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsbas.59145088 ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.1038/s41467-023-35961-y
)
)
[Languages] => Array
(
[0] => Array
(
[Text] => English
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => Carcinoma
[Type] => general
)
[1] => Array
(
[SubjectFull] => Non-Small-Cell Lung* / drug therapy
[Type] => general
)
[2] => Array
(
[SubjectFull] => Non-Small-Cell Lung* / genetics
[Type] => general
)
[3] => Array
(
[SubjectFull] => ErbB Receptors / genetics
[Type] => general
)
[4] => Array
(
[SubjectFull] => Humans
[Type] => general
)
[5] => Array
(
[SubjectFull] => Lung Neoplasms* / drug therapy
[Type] => general
)
[6] => Array
(
[SubjectFull] => Lung Neoplasms* / genetics
[Type] => general
)
[7] => Array
(
[SubjectFull] => Mutation
[Type] => general
)
[8] => Array
(
[SubjectFull] => Protein Kinase Inhibitors / pharmacology
[Type] => general
)
[9] => Array
(
[SubjectFull] => Protein Kinase Inhibitors / therapeutic use
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Juliann Chmielecki
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Jhanelle E Gray
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Ying Cheng
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Yuichiro Ohe
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Fumio Imamura
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Byoung Chul Cho
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Meng-Chih Lin
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Margarita Majem
)
)
)
[8] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Riyaz Shah
)
)
)
[9] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Yuri Rukazenkov
)
)
)
[10] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Alexander Todd
)
)
)
[11] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Aleksandra Markovets
)
)
)
[12] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => J Carl Barrett
)
)
)
[13] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Ryan J Hartmaier
)
)
)
[14] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Suresh S Ramalingam
)
)
)
[15] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Cho, Byoung Chul
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 01
[Type] => published
[Y] => 2023
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 20411723
)
[1] => Array
(
[Type] => issn-locals
[Value] => edsbas
)
[2] => Array
(
[Type] => issn-locals
[Value] => edsbas.oa
)
)
)
)
)
)
)
|
| IllustrationInfo |